Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort

Acute Myocardial Infarction Clinical Trial

Official title:

Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort - a Prospective, Multicenter Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05862103
• Other study ID #: KY2022-266
• Status: Recruiting
• Start date: December 20, 2022
• Est. completion date: December 30, 2026

Study information

• Verified date: May 2023
• Source: Harbin Medical University
• Contact: Xiling Zhang, MD
• Phone: +86 13804608748
• Email: xlzhangdr[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and 5 years after discharge to acquire the patients' medication, health status, and major adverse cardiovascular and cerebrovascular events, including death, heart failure, rehospitalization, re-myocardial infarction, revascularization, stroke, malignant arrhythmia, and bleeding events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15000
• Est. completion date: December 30, 2026
• Est. primary completion date: August 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• AMI survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" and completed the 1-year visit.
• Telephone to obtain informed consent from the subjects/family members of the subjects.

Exclusion Criteria:

• Not available

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Adverse Event
• Infarction
• Myocardial Infarction

Intervention

Other:
• Treatment Strategies
AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion

Locations

Country	Name	City	State
China	Beijing An Zhen Hospital, Capital Medical University	Beijing	Beijing
China	Beijing Chao-Yang Hospital, Capital Medical University	Beijing	Beijing
China	Peking Univerisity People'Hospital	Beijing	Beijing
China	Peking University First Hospital	Beijing	Beijing
China	The Second Hospital of Jilin University	Changchun	Jilin
China	Xinqiao Hospital Army Medical University	Chongqing	Sichuan
China	The econd Affiliated Hospital of Dalian Medical University	Dalian	Liaoning
China	Daqing Oil Field Hospital	Daqing	Heilongjiang
China	Guangdong general hospital	Guangzhou	Guangdong
China	The Second Affiliated Hospital of Nanchang University	Nanchang	Jiangxi
China	Zhongda Hospital Southeast University	Nanjing	Jiangsu
China	The first affiliated hospital of Guangxi medical university	Nanning	Guangxi
China	General Hospital of Northern Theater Command of the Chinese People's Liberation Army	Shenyang	Liaoning
China	Second hospital of hebei medical university	Shijiazhuang	Hebei
China	The General Hospital of Tianjin Medical University	Tianjin	Tianjin
China	Tianjin Chest Hospital	Tianjing	Tianjin
China	First Affiliated Hospital of Xinjiang Medical University	Ürümqi	Xinjiang
China	Xijing Hospital of Air Force Military Medical University	Xi'an	Shanxi
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Yu Bo

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of MACCE	the incidence of MACCE (death, heart failure, rehospitalization, re-myocardial infarction, re-myocardial revascularization, stroke, malignant arrhythmia, bleeding events, etc.) in AMI patients	5 years after discharge
Secondary	Differences of MACCE between the optimized group and the non-optimized group	Differences of the MACCE between the optimized group and the non-optimized group	5 years after discharge
Secondary	Differences of the MACCE between OCT-guided group and the coronary angiography -guided group	Differences of the MACCE between OCT-guided group and the coronary angiography -guided group	5 years after discharge
Secondary	Differences of MACCE between defer PCI group and direct PCI group	Differences of MACCE between defer PCI group and direct PCI group	3 and 5 years after discharge
Secondary	Differences of the MACCE incidence between cardiac rehabilitation quality improvement group and non-cardiac rehabilitation group	Differences of the MACCE incidence between cardiac rehabilitation quality improvement group and non-cardiac rehabilitation group	5 years after discharge